Li Zhuang

Kunming, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Journal: JAMA
Published: August 10, 2026

AI-Driven Prediction of Cancer Pain Episodes: A Hybrid Decision Support Approach.

AI-Driven Prediction of Cancer Pain Episodes: A Hybrid Decision Support Approach.

Journal: IEEE journal of biomedical and health informatics
Published: May 19, 2026

Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy.

Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy.

Journal: Frontiers in oncology
Published: May 17, 2026

International Consensus on Severe Lung Cancer-The Second Edition.

International Consensus on Severe Lung Cancer-The Second Edition.

Journal: Translational lung cancer research
Published: March 21, 2026

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance.

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance.

Journal: Frontiers in oncology
Published: January 01, 2026

Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma.

Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma.

Journal: Chinese medical journal
Published: November 11, 2025

Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.

Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 26, 2025

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance.

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance.

Journal: Frontiers in oncology
Published: February 24, 2025

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Journal: Signal transduction and targeted therapy
Published: January 18, 2025

Development of a nomogram for predicting cancer pain in lung cancer patients: An observational study.

Development of a nomogram for predicting cancer pain in lung cancer patients: An observational study.

Journal: Medicine
Published: November 29, 2024

Factors Associated With Radiological Lung Growth Rate After Lobectomy in Patients With Lung Cancer.

Factors Associated With Radiological Lung Growth Rate After Lobectomy in Patients With Lung Cancer.

Journal: The Journal of surgical research
Published: July 14, 2023

MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells.

MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells.

Journal: PloS one
Published: June 01, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026